Molecular Taxonomy of Surgically-harvested Ocular Tissues Defined by Single-cell Transcriptomics

NCT04682054 | Unknown DMC

• 1 other identifier: Eyesinglecell
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

The surgically-harvested eye tissue (ie. vitreous-retinal proliferative membrane, outflow pathway, retinas, and pterygium) is a complex tissue responsible for maintaining intraocular homeostasis or mediating ocular pathogenesis. Dysfunction of one or more resident cell types within the tissues results in different ocular disorder, leading to vision loss, or even blindness. In this study, we aim to use single-cell RNA sequencing to generate a comprehensive cell atlas of surgically-harvested eye tissues.

Conditions

Diabetic Retinopathy; Proliferative Vitreoretinopathy; Pterygium; Glaucoma

Outcome Measures

Primary Outcomes (1)

• counts of each cell type

  single-cell sequencing identify what cells and the counts within the eye tissue

  1 month

Study Arms (1)

surgically-removed eye tissue

EXPERIMENTAL

Procedure: ocular surgery

Interventions

ocular surgery PROCEDURE

surgery to remove the pathological eye tissue

surgically-removed eye tissue

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with ocular diseases and require surgery intervention.
• The surgery intervention remove pathological tissue during surgery.
• Patients consent to the treatment and single-cell sequencing.

You may not qualify if:

• \. Surgically removed eye tissue cannot meet with the quality control of single-cell sequencing (mainly the tissue weight and cell counts);

Sponsors & Collaborators

• The First Affiliated Hospital with Nanjing Medical University: lead

Study Sites (1)

First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, 210029, China

Location

Related Publications (4)

• Tan WJ, Wang MM, Castagnoli PR, Tang T, Chan ASY, Lim TS. Single B-Cell Genomic Analyses Differentiate Vitreoretinal Lymphoma from Chronic Inflammation. Ophthalmology. 2021 Jul;128(7):1079-1090. doi: 10.1016/j.ophtha.2020.11.018. Epub 2020 Nov 20.

  PMID: 33221324 BACKGROUND

• Wynne N, Carroll J, Duncan JL. Promises and pitfalls of evaluating photoreceptor-based retinal disease with adaptive optics scanning light ophthalmoscopy (AOSLO). Prog Retin Eye Res. 2021 Jul;83:100920. doi: 10.1016/j.preteyeres.2020.100920. Epub 2020 Nov 6.

  PMID: 33161127 BACKGROUND

• de Bruijn SE, Fiorentino A, Ottaviani D, Fanucchi S, Melo US, Corral-Serrano JC, Mulders T, Georgiou M, Rivolta C, Pontikos N, Arno G, Roberts L, Greenberg J, Albert S, Gilissen C, Aben M, Rebello G, Mead S, Raymond FL, Corominas J, Smith CEL, Kremer H, Downes S, Black GC, Webster AR, Inglehearn CF, van den Born LI, Koenekoop RK, Michaelides M, Ramesar RS, Hoyng CB, Mundlos S, Mhlanga MM, Cremers FPM, Cheetham ME, Roosing S, Hardcastle AJ. Structural Variants Create New Topological-Associated Domains and Ectopic Retinal Enhancer-Gene Contact in Dominant Retinitis Pigmentosa. Am J Hum Genet. 2020 Nov 5;107(5):802-814. doi: 10.1016/j.ajhg.2020.09.002. Epub 2020 Oct 5.

  PMID: 33022222 BACKGROUND

• van Zyl T, Yan W, McAdams A, Peng YR, Shekhar K, Regev A, Juric D, Sanes JR. Cell atlas of aqueous humor outflow pathways in eyes of humans and four model species provides insight into glaucoma pathogenesis. Proc Natl Acad Sci U S A. 2020 May 12;117(19):10339-10349. doi: 10.1073/pnas.2001250117. Epub 2020 Apr 27.

  PMID: 32341164 BACKGROUND

MeSH Terms

Conditions

Diabetic Retinopathy; Vitreoretinopathy, Proliferative; Pterygium; Glaucoma

Interventions

Ophthalmologic Surgical Procedures

Condition Hierarchy (Ancestors)

Retinal Diseases; Eye Diseases; Diabetic Angiopathies; Vascular Diseases; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases; Conjunctival Diseases; Ocular Hypertension

Intervention Hierarchy (Ancestors)

Surgical Procedures, Operative

Central Study Contacts

Zizong Hu, PhD, MD

CONTACT

+8615195960100; huzizhong@njum.edu.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 7, 2020
• First Posted: December 23, 2020
• Study Start: January 15, 2021
• Primary Completion: December 31, 2021
• Study Completion: December 31, 2021
• Last Updated: December 23, 2020

Record last verified: 2020-12

Data Sharing

• IPD Sharing: Will share
• Shared Documents: CSR, ANALYTIC CODE

Locations

CN (1)